CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company's operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. bioCSL segment manufactures, sells and distributes vaccines, antivenoms and other pharmaceutical products primarily in Australia and New Zealand; as well as also manufactures and markets in vitro diagnostic products through Immunohaematology. It operates primarily in Germany, Switzerland and the United States. CSL Ltd. is headquartered in Parkville, Australia.
| Revenue (Most Recent Fiscal Year) | $14.80B |
| Net Income (Most Recent Fiscal Year) | $2.64B |
| PE Ratio (Current Year Earnings Estimate) | 24.28 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 1.94 |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 20.05 |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $20.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $3.01 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 968.42M |
| Free Float | -- |
| Market Capitalization | $77.25B |
| Average Volume (Last 20 Days) | 0.08M |
| Beta (Past 60 Months) | 0.79 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.03% |
| Annual Dividend (Based on Last Quarter) | $1.20 |
| Dividend Yield (Based on Last Quarter) | 1.50% |